Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Classical hematology 1

Conditions

Thrombocytopenia 7Leukemia, Myeloid, Acute 6Leukemia 5Myelodysplastic Syndromes 3Leukemia, Myelomonocytic, Chronic 2Jacobs syndrome 2Recurrence 1Purpura, Thrombocytopenic, Idiopathic 1Primary Myelofibrosis 1Pathologic Complete Response 1Myeloproliferative Disorders 1Multiple Myeloma 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Erythroblastic, Acute 1Leukemia, Eosinophilic, Acute 1Leukemia, Basophilic, Acute 1Congenital Abnormalities 1Blast Crisis 1Anemia, Refractory, with Excess of Blasts 1Anemia 1

Interventions

Mycophenolic Acid 25fludarabine phosphate 21Whole-Body Irradiation 21Cyclophosphamide 21Cyclosporine 16Tacrolimus 15Peripheral Blood Stem Cell Transplantation 15Busulfan 14fludarabine 11Cord Blood Stem Cell Transplantation 9Methotrexate 8Melphalan 8Granulocyte Colony-Stimulating Factor 8Cytarabine 8Antilymphocyte Serum 8Filgrastim 7Thiotepa 6Etoposide 6sargramostim 4merphos 4Radiotherapy 4Drug Therapy 4Cyclosporins 4Azacitidine 4thymoglobulin 3Vorinostat 3Sirolimus 3Lenalidomide 3Idarubicin 3tipifarnib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Anemia, Refractory, with Excess of Blasts × eltrombopag × Clear all
NCT01772420 2023-07-27

Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia

Albert Einstein College of Medicine

Phase 2 Completed
52 enrolled 21 charts
Classical hematologyOther hematologic neoplasm

Anemia, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡